Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Key Highlights
- ➤Elicio (ELTX) will present additional Phase 2 AMPLIFY-7P camupepimut results at SITC 2026
- ➤AMPLIFY-7P randomized Phase 2 study enrolled 144 patients across 24 U.S. clinical sites
- ➤Late-breaking data will examine KRAS-specific T-cell responses and clinical outcomes
- ➤Elicio will present expanded antigen-agnostic intratumoral AMP-platform preclinical data
Expert Statements
Darrell J. Irvine, Presenter, The Scripps Research Institute
“Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine”
Christopher M. Haqq, Presenter
“Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial”
Martin Steinbuck, Presenter
“Direct intratumoral delivery of amphiphilic immunomodulators induces durable anti-tumor efficacy”
* Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer * Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer’s (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.
Get started
Create a free account to read the full story.